

**OnDemand Complicated Cataracts Cases: A Multi-Disciplinary Approach 2024**

**Monday, November 18, 2024 — Tuesday, November 18, 2025**

*Wills Eye Auditorium*

**Conference Description:**

With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.

This conference will offer a deep dive into complicated cataract cases and their intersection with other ophthalmology specialties, specifically cornea, glaucoma, and retina.

**At the conclusion of the course, participants should be able to:**

1 Evaluate newly available lens options

2 Implement the use of new technologies and devices in cataract care

3 Strategize care plans for complicated situations involving cataracts concurrent with glaucoma, corneal, and/or retinal issues

4 Educate patients on appropriate lens selection

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

**Credit Statement Designation:**

Wills Eye Hospital designates this Enduring Material for a maximum of 3.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Ayan Chatterjee, MD | Faculty | Honoraria-Alcon (Relationship has ended) - 10/09/2024 |
| Janine G Tabas, MD | Faculty | Nothing to disclose - 10/09/2024 |
| Douglas Wisner, MD | Faculty | Advisor-Zeiss|Advisor-Haag-Streit - 03/06/2024 |
| Ravi Patel, MD, MBA | Faculty | Speakers Bureau-Allergan|Speakers Bureau-Oyster Point Pharmaceuticals|Consulting Fee-Bio-Tissue|Consulting Fee-Johnson & Johnson|Grant or research support-Ocular Therapeutix (Relationship has ended)|Consulting Fee-Kala Pharmaceuticals (Relationship has ended)|Consulting Fee-Bausch + Lomb - 10/29/2024 |
| Christina McGowan, MD | Faculty | Nothing to disclose - 10/14/2024 |
| Mark F Pyfer, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Johnson & Johnson|Paid consultant-Johnson & Johnson|Independent Contractor (included contracted research)-Sight Sciences (Relationship has ended)|Speakers Bureau-Sight Sciences|Speakers Bureau-Rayner Surgical|Independent Contractor (included contracted research)-Tarsus (Relationship has ended) - 08/09/2024 |
| Drew Chronister, MD | Faculty | Nothing to disclose - 10/09/2024 |
| Melissa Sieber, MD | Faculty, Planner | Nothing to disclose - 03/14/2024 |
| Brett Weinstock, MD | Faculty, Planner | Nothing to disclose - 06/07/2024 |
| Colleen Halfpenny, MD | Faculty | Nothing to disclose - 10/23/2024 |
| David Stephens, MD | Faculty | Consulting Fee-Alcon|Speakers Bureau-Allergan|Speakers Bureau-Glaukos Corporation|Speakers Bureau-RxSight|Speakers Bureau-Lensar|Speakers Bureau-Ianterk - 11/16/2024 |
| Kristin DiDomenico, MD | Faculty | Consulting Fee-Santen Pharmaceuticals (Relationship has ended) - 10/17/2024 |
| John C Anhalt, MD | Faculty | Nothing to disclose - 11/16/2024 |
| Alice Williams, MD | Faculty | Nothing to disclose - 10/05/2024 |
| Michael Wong, MD | Faculty | Nothing to disclose - 10/10/2024 |
| Anton Orlin, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Allergan (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Zeiss (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Apellis Pharmaceuticals (Relationship has ended) - 10/09/2024 |
| Jordan Deaner, MD | Faculty | Consulting Fee-EyePoint Pharmaceuticals (Relationship has ended)|Consulting Fee-Alimera Sciences (Relationship has ended)|Consulting Fee-Genentech (Relationship has ended)|Consulting Fee-Bausch + Lomb (Relationship has ended)|Consulting Fee-Regeneron (Relationship has ended) - 09/25/2024 |
| Alessandra K Intili, MD | Planner | Nothing to disclose - 09/24/2024 |
| Michael Pro, MD | Faculty | Nothing to disclose - 01/08/2024 |

